Enliven Therapeutics
ELVN
121 hedge funds and large institutions have $984M invested in Enliven Therapeutics in 2025 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 43 increasing their positions, 35 reducing their positions, and 13 closing their positions.
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
23% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 35
7% more funds holding
Funds holding: 113 → 121 (+8)
0.24% more ownership
Funds ownership: 101.57% → 101.81% (+0.24%)
12% less capital invested
Capital invested by funds: $1.12B → $984M (-$133M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
81% less call options, than puts
Call options by funds: $4K | Put options by funds: $21K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$10.1M |
| 2 |
Blackstone Inc
New York
|
+$8.37M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$5.14M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.01M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$13.2M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$6.61M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.3M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$4.07M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$3.55M |
ELVN Hedge Fund Activity: Q1 2025 in Review
121 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q1 2025, worth a combined $984M — down 12% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ELVN positions and 13 closed out — a net gain of 8 holders — while 43 added to existing stakes and 35 trimmed.
The largest buyer was Commodore Capital, adding an estimated $10.1M. The largest seller was Citadel Advisors, cutting an estimated $13.2M.
- 121 institutional investors held Enliven Therapeutics (ELVN) as of Q1 2025, up from 113 in Q4 2024.
- Funds reported $984M of Enliven Therapeutics stock for Q1 2025, down 12% quarter-over-quarter.
- 21 funds opened new Enliven Therapeutics positions in Q1 2025 and 13 closed out, a net change of +8 holders.
- The largest Enliven Therapeutics buyer in Q1 2025 was Commodore Capital, an estimated $10.1M added.
- The largest Enliven Therapeutics seller in Q1 2025 was Citadel Advisors, an estimated $13.2M sold.
Based on aggregated 13F filings for Q1 2025.